DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
DarioHealth Corp. (DRIO) filed a Current Report on Form 8-K dated November 5, 2025. The filing details the entry into a material definitive agreement involving an amendment to its existing credit facility with Callodine Commercial Finance, LLC and other lenders.
Key Financial Metrics and Debt Terms
The filing focuses on debt restructuring rather than operational performance metrics. Key financial terms established include:
- Minimum Liquidity Covenant: Replaced the minimum cash covenant with a requirement to maintain $10,000,000 in minimum consolidated unencumbered liquid assets.
- Reporting Requirements: A monthly 13-week cash-flow reporting requirement is triggered if liquidity falls below $11,000,000 (subject to an EBITDA exception).
- Amendment Fee: The Company paid a one-time fee of $150,000 to the agent.
- Exit Fee: Increased by an additional $150,000, potentially waivable upon a change-of-control prepayment.
- Warrant and Conversion Price Adjustments: The exercise price of Lender Warrants was reduced from $16.556 to $15.3495 per share. The conversion price for up to $2,500,000 of the loan facility was reduced from $19.866 to $15.3495 per share.
The filing text does not provide current values for revenue, profit, cash flow, margins, or total debt outstanding.
Material Changes and Covenant Adjustments
Significant changes to the credit agreement include:
- Covenant Reset: Financial covenants were reset, and testing for the second and third quarters of 2025 was waived.
- Additional Funding: Clarification that an additional funding of $2,500,000 by the Lenders is uncommitted and discretionary.
- Equity Terms: Reduction in warrant exercise and loan conversion prices to align with current market conditions.
Outlook, Risks, and Management Commentary
The amendment reflects a strategic move to manage liquidity and covenant compliance. The requirement for monthly cash-flow reporting when liquidity is below $11,000,000 indicates a heightened focus on short-term cash management. The uncommitted nature of the potential $2,500,000 additional funding represents a contingency rather than a guaranteed liquidity source.
Investor Verification Checklist
- Verify the Company's current consolidated unencumbered liquid assets against the new $10,000,000 covenant threshold.
- Review the attached Exhibit 10.1 for the full text of the Credit Agreement Amendment and specific EBITDA exceptions.
- Assess the dilution impact of the reduced warrant exercise price ($15.3495) and loan conversion price.
- Confirm whether the Company currently meets the liquidity threshold to avoid the monthly 13-week cash-flow reporting requirement.